GSK plc Files Annual Report with U.S. Securities Regulator
Pharmaceutical company GSK plc has filed its annual Form 20-F with the U.S. Securities and Exchange Commission, detailing its financial performance and operations for the fiscal year ending December 31, 2018.
Pharmaceutical firm GSK plc has submitted its annual Form 20-F to the U.S. Securities and Exchange Commission (SEC) on March 15, 2019. The filing provides an overview of the company's operational and financial status for the fiscal year that concluded on December 31, 2018.
GSK, headquartered in Brentford, England, is confirmed as a reporting issuer that is not a well-known seasoned issuer. The company operates as a U.S.-listed entity and has met its filing obligations for the preceding 12-month period.
The Form 20-F, which serves as the annual report for foreign private issuers, encompasses a range of information including details on the company's directors, senior management, and advisors, as well as offer statistics, key information, company overview, and operating and financial reviews.
Regarding financial reporting, GSK has indicated that its financial statements are prepared in accordance with International Financial Reporting Standards (IFRS). The company is not a shell company and meets the criteria for a large accelerated filer, adhering to the reporting requirements set forth by ASIC and SEC regulations.